Uploaded December 2024 | Updated November 2026, 3 hours ago
At the 2024 RNDS, Dr. Michael Levy of Massachusetts General Hospital discussed various therapeutic approaches for MOG antibody disease (MOGAD), transverse myelitis (TM), and neuromyelitis optica spectrum disorder (NMOSD), including acute therapy, preventive therapy, regenerative therapy, and symptomatic trials. Details were provided on specific trials such as the rozanolixizumab trial for MOGAD and the use of satralizumab for NMOSD [00:00:58]. Another focus was on a study investigating the impact of a dairy-free diet on MOG antibody levels [00:01:58]. Dr. Levy also mentioned acute treatment trials and the potential impact of cannabis-based products on improving quality of life for those diagnosed with NMOSD [00:11:16]. He concluded by answering audience questions [00:15:34]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Levy.pdf
00:00 Introduction to MOGAD, TM, and NMOSD Trials
00:13 Understanding Acute and Preventive Therapies
00:32 Exploring Regenerative and Symptomatic Therapies
00:58 Current Trials in NMOSD
01:58 MOGAD Trials
02:28 Mechanism of Action: FcRn Blockers
04:19 Trial Design and Enrollment
05:38 Enspryng Trials for MOGAD
07:39 Dairy-Free Diet Study
11:16 Acute Treatment Trials
13:54 Nabiximols for NMOSD Quality of Life
15:28 Audience Questions
At the 2024 RNDS, Dr. Michael Levy of Massachusetts General Hospital discussed various therapeutic approaches for MOG antibody disease (MOGAD), transverse myelitis (TM), and neuromyelitis optica spectrum disorder (NMOSD), including acute therapy, preventive therapy, regenerative therapy, and symptomatic trials. Details were provided on specific trials such as the rozanolixizumab trial for MOGAD and the use of satralizumab for NMOSD [00:00:58]. Another focus was on a study investigating the impact of a dairy-free diet on MOG antibody levels [00:01:58]. Dr. Levy also mentioned acute treatment trials and the potential impact of cannabis-based products on improving quality of life for those diagnosed with NMOSD [00:11:16]. He concluded by answering audience questions [00:15:34]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Levy.pdf
00:00 Introduction to MOGAD, TM, and NMOSD Trials
00:13 Understanding Acute and Preventive Therapies
00:32 Exploring Regenerative and Symptomatic Therapies
00:58 Current Trials in NMOSD
01:58 MOGAD Trials
02:28 Mechanism of Action: FcRn Blockers
04:19 Trial Design and Enrollment
05:38 Enspryng Trials for MOGAD
07:39 Dairy-Free Diet Study
11:16 Acute Treatment Trials
13:54 Nabiximols for NMOSD Quality of Life
15:28 Audience Questions
![1214. Self Identity and Finding Meaning Following Diagnosis
In this Ask the Expert episode, Krissy Dilger of SRNA spoke with Susan Y. Wegener, LCSW, a licensed clinical social worker, about coping with a chronic diagnosis and its emotional adjustments, referencing Kübler-Ross’ stages of grief [00:03:45]. Susan discussed the importance of self identity transformation post-diagnosis and the need for patience and self-compassion in finding new ways to move forward [00:08:34]. The value of inner strength, setting priorities, and support groups for reducing isolation and fostering compassion was emphasized [00:15:20]. The discussion concluded with a focus on post-traumatic growth, highlighting greater life appreciation and mental flexibility as key coping strategies [00:16:01].
Susan Y. Wegener, LCSW is a licensed clinical social worker who maintains a private psychotherapy practice in Austin, TX. Her clinical practice specializes in work with individuals coping with chronic medical diagnoses. She completed her undergraduate degree, in Psychology, from Skidmore College, Saratoga Springs N.Y., 1993 and her graduate degree, in Social Work from Columbia University, New York City in 1995. In addition to her private practice, she has worked in multiple medical settings throughout her career and helped to empower and support individuals from diagnosis through the adjustment process. She became a Partner in Care for the National Multiple Sclerosis Society in 2017 and is passionate about her work with individuals diagnosed with MS and various other neurological diagnoses. In her free time, she enjoys singing in a local chorus, cooking, swimming, and spending time with her family. Please see the following link to her workbook “Hold on to Hope.”
https://www.amazon.com/Hold-Hope-Overview-Strategies-Chronic/dp/1512218715
00:00 Introduction to the Podcast
00:37 Meet the Expert: Susan Wagner
01:00 Coping with a Chronic Diagnosis
01:47 The Emotional Adjustment Process
05:36 Understanding Self Identity Post-Diagnosis
08:34 Dealing with Denial
10:39 Coping Strategies for Shifting Self Identity
14:08 Finding Meaning and Purpose
14:26 Exploring the Impact of Diagnosis
15:25 Reflecting on Values and Strengths
16:06 Coping Strategies for Finding Meaning
16:29 The Role of Relationships and Support Systems
18:05 Prioritizing Self-Care and Realistic Goals
20:04 Finding Meaning in Suffering
20:15 The Concept of Post-Traumatic Growth
24:52 The Importance of Stillness and Self-Compassion
28:31 Mental Flexibility and Creative Thinking
30:02 Conclusion and Final Thoughts 1214. Self Identity and Finding Meaning Following Diagnosis](https://i.ytimg.com/vi/8-4AgHzzMrA/mqdefault.jpg)
![Community Meets Clinic 304. Dr. Ayşe Altıntaş
The Community Meets Clinic podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode, Krissy Dilger of SRNA spoke with Dr. Ayşe Altıntaş, Professor of Neurology at Koç University School of Medicine in Istanbul, Turkey, which has been designated as a Center of Excellence in Rare Neuroimmune Disorders. Dr. Altıntaş described the unmet needs in rare neuroimmune disorders and noted her role on an international panel developing updated NMOSD diagnostic criteria [00:03:40]. She outlined current research on mechanisms of optic neuritis, pregnancy complications and aquaporin-4 antibodies, and developing accessible biomarkers beyond CSF with a future goal of remote monitoring [00:06:01]. Dr. Altıntaş also explained Koç University’s multidisciplinary demyelinating disease center model, emphasizing coordinated consultations, advanced MRI capabilities, shared decision-making, and the value of specialized centers, while expressing hope due to rapid advances in biomarkers and targeted therapies [00:11:43]. You can view the medical profile of Dr. Ayşe Altıntaş here:
https://www.kuh.ku.edu.tr/doctors/ayse-altintas
Ayşe Altıntaş, MD is a professor of neurology at Koç University School of Medicine in Istanbul, Türkiye. She graduated from Ege University Faculty of Medicine in 1986 and completed her neurology residency there in 1992. She received early training in neuroimmunology as a fellow at Mayo Clinic under Prof. Moses Rodriguez and later continued her research at Mayo Clinic with Prof. Claudia Lucchinetti and Prof. Brian Weinshenker, focusing on the animal model, immunopathology, and imaging correlates of multiple sclerosis.
Prof. Altıntaş served at Istanbul University Cerrahpaşa School of Medicine for 23 years before joining Koç University in 2018, where she established a neuroimmunology laboratory and continues to lead clinical and translational research. Her work focuses on multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD) and MOG antibody-associated diseases (MOGAD), with an emphasis on biomarkers and disease mechanisms. She is actively involved in international organizations, including BioMS-eu, The MOG Project, Siegel Rare Neuroimmune Association (SRNA), MEDEN, the MSBase Scientific Leadership Group, and the Guthy-Jackson Charitable Foundation International Scientific Consortium.
00:00 Welcome and Guest Intro
01:39 Why Neurology
03:40 Choosing Rare Disorders
06:01 Current Research Projects
11:43 Clinic Team and Workflow
15:48 Advanced Imaging and Coordination
17:20 Self Care and Balance
20:20 Advice for New Patients
22:17 Hope for the Future
24:34 Closing Community Meets Clinic 304. Dr. Ayşe Altıntaş](https://i.ytimg.com/vi/8Ih_dfaRGS0/mqdefault.jpg)





![2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Linda Nguyen, MD, PhD, of UT Southwestern Medical Center and Childrens Health, spoke about predicting relapse in children with MOG antibody disease (MOGAD) [00:00:52]. She explained why some children have a single attack while others relapse, the question of starting preventive treatment, and what earlier studies have found [00:01:16]. She described a study across three pediatric centers in the United States, with 225 children identified and 187 followed for at least six months [00:05:42]. Dr. Nguyen reported that 31 percent relapsed, when relapses happened, and which first-attack features mattered, including acute disseminated encephalomyelitis (ADEM) combined with another presentation [00:08:25]. She showed that repeat MOG antibody tests months after the first attack were the strongest clue, with negative or low results reassuring and higher titers linked to more relapses [00:15:00].
Linda Nguyen, MD, PhD, is an Assistant Professor of Pediatrics at UT Southwestern Medical Center and Childrens Health in Dallas, Texas. She completed her MD and PhD training at West Virginia University in 2017, a pediatric neurology residency at UC San Diego in 2022, and a neuroimmunology fellowship at UT Southwestern.
00:00 Introduction
00:52 Predicting Relapse in Children
01:16 What the Talk Will Cover
02:48 What Earlier Studies Found
05:42 What This Study Adds
06:51 The Two Research Questions
08:25 How Many Children Relapsed
09:55 First-Attack Clues
15:00 Antibody Tests Over Time
17:34 Key Takeaways
18:33 Limits and Next Steps 2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse](https://i.ytimg.com/vi/9vxLdj0IAVI/mqdefault.jpg)

![1311. Understanding Myelitis: Efforts to Update Diagnostic Criteria
In this episode of the SRNA Ask the Expert podcast moderated by Dr. GG deFiebre, Dr. Kyle Blackburn and Dr. Benjamin Greenberg discussed the need for updated diagnostic criteria for myelitis. Dr. Blackburn explained the term myelitis and the importance of precise terminologies for accurate diagnoses and research [00:05:10]. Dr. Greenberg elaborated on the advancements in testing and understanding of associated disorders like NMOSD and MOGAD since 2002 [00:11:10]. Both experts stated that the shift from transverse myelitis to myelitis will aid future research, treatments, and patient care [00:17:27]. They reassured patients that these changes would essentially refine their care but not alter it dramatically [00:23:40]. They encouraged patients to stay informed and communicate with their healthcare providers about these updates [00:28:58].
Kyle Blackburn, MD is an Assistant Professor in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He specializes in neuroimmunology and has clinical interests in antibody-mediated neurologic disorders, including autoimmune encephalitis, epilepsy, and ataxias; neurologic complications of cancers, including paraneoplastic disorders and checkpoint inhibitor/CAR T-cell toxicity; and demyelinating disorders, including sarcoidosis, neuromyelitis optica, myelin oligodendrocyte glycoprotein (MOG)-associated disease, and multiple sclerosis.
Dr. Blackburn earned his medical degree at the University of Kentucky College of Medicine. He performed his residency in adult neurology at UT Southwestern, serving his final year as Chief Resident, and stayed to complete a fellowship in neuroimmunology, during which he earned the James T. Lubin Clinician Scientist Award from the Siegel Rare Neuroimmune Association (SRNA). He joined the UT Southwestern faculty in 2020.
Benjamin M. Greenberg, M.D., M.H.S. is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children’s Medical Center.
Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago’s Rush Presbyterian-St. Luke’s Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor’s degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation’s first dedicated Transverse Myelitis Center.
Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children’s Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients.
00:00 Introduction
00:58 Overview of Myelitis and Diagnostic Criteria
02:57 Historical Context and Importance of Updated Criteria
05:10 Challenges with Current Terminology
11:10 Changes in Understanding and Diagnostic Approaches
17:27 Implications for Patients and Clinical Practice
23:40 Impact on Research and Future Directions
28:58 Patient Advocacy and Resources
31:17 Conclusion and Final Thoughts 1311. Understanding Myelitis: Efforts to Update Diagnostic Criteria](https://i.ytimg.com/vi/AisPcfLkAz8/mqdefault.jpg)
